Tag Archives: roux en y

Obesity Co-Morbidities, Clinical Management and Drug/Device Market Growth

Obesity puts a burden on so many aspects of life that the socioeconomic cost is almost inevitably enormous—as well as challenging to quantify. At the individual level, there is the lower quality of life, days missed from work, decreased wages, premature retirement, potentially unemployment, and the medical costs of related illnesses, which may include depression, [...]

Obesity at or near the top of the list in driving U.S. healthcare costs

The worldwide market for bariatric surgical devices — the surgical device treatment of obesity — is growing at an alarming rate as a result of increasing prevalence in obesity.  Data from the World Health Organization and International Obesity Task Force (see report #S825) illustrates how significant both the direct and indirect costs are that are [...]

Obesity treatment trends globally for drugs, devices

The ideal treatment for weight loss is lifestyle modification through diet and exercise: as Aristotle said, “Moderation in all things.” However, the compliance rate for this method of treatment is very low: according to some studies, less than 2% of obese people who lose excess weight through diet and exercise are successful in [...]

Obesity surgery outperforms medical therapy

From Report #S825, "Worldwide Market for the Clinical Management of Obesity, 2007-2015."
With a significant increase in obesity within developed countries, many researchers and product developers are working hard to develop new therapies. Surgical devices utilized to treat obesity have proven particularly useful and in some cases, have even outperformed nonsurgical therapies.

Obesity represents one of the [...]

U.S. Will Increasingly Dominate (Unfortunately) the Worldwide Bariatric Device Market

The US and Canadian market for bariatric devices is growing at stunning rate, driven by an increasingly prevalent patient population, the increasing capability of physicians to perform bariatric procedures and a recognition by healthcare systems and third party payers to address the problem as a lynchpin for a condition that otherwise will drive up other, [...]